We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Vertex Pharmaceuticals’ cystic fibrosis drug Trikafta (elexacaftor/tezacaftor/ivacaftor) will need a dramatic price cut to be cost effective, the Institute for Clinical and Economic Review (ICER) found in a new analysis. Read More
Drugmakers are reporting shortages of two drugs needed for ventilator patients as demand increases due to COVID-19, propofol and dexmedetomidine. Read More
Novartis and Aurobindo have terminated their $1 billion deal to sell the Sandoz U.S. generic oral solids and dermatology business to Aurobindo. Read More
The company said that it suspended its exclusivity to enable a greater supply of the drug should additional trials or evaluations show it has potential in treating COVID-19. Read More